miR-524-5p reduces the progression of the BRAF inhibitor-resistant melanoma

miR-524-5p reduces the progression of the BRAF inhibitor-resistant melanoma

BRAF inhibitors were approved for the treatment of BRAF-mutant melanoma. However, most patients acquire the resistance to BRAF inhibitors after several months of treatment. miR-524-5p is considered as a tumor suppressor in many cancers, including melanoma. In this study, we investigated the biologic...

Full description

Bibliographic Details
Main Authors: Mai-Huong Thi Nguyen, Chen-Huan Lin, Szu-Mam Liu, Azusa Miyashita, Hironobu Ihn, Hsuan Lin, Chi Hou Ng, Jen-Chieh Tsai, Ming-Hong Chen, Mu-Shiun Tsai, In-Yu Lin, Shu-Chen Liu, Long-Yuan Li, Satoshi Fukushima, Jean Lu, Nianhan Ma
Format: Article
Language:English
Published: Elsevier 2020-12-01
Series:Neoplasia: An International Journal for Oncology Research
Subjects:
Melanoma
miRNA
BRAF inhibitor
Resistance
miR-524-5p
Online Access:http://www.sciencedirect.com/science/article/pii/S1476558620301640

Internet

http://www.sciencedirect.com/science/article/pii/S1476558620301640

Similar Items